BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval
Asher Mullard
Topics & Concepts
Drug approvalMEK inhibitorMedicinePharmacologyCancer researchDrugChemistryKinaseMAPK/ERK pathwayBiochemistryMelanoma and MAPK PathwaysCancer Mechanisms and TherapySynthesis and biological activity